Infectious Disease
Karolinska Development’s infectious disease projects involve, among other areas, malaria, which causes two million deaths each year,
mostly of children. Products against the most common invasive fungal infections, Aspergillus and Candida, are also under development.
| Infectious Disease | Concept Development | Lead Discovery | Lead Optimization | Preclinical Development | Phase I | Phase II | Phase III | Launch | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||||||
|
|
||||||||||||||||
Dilaforette ABSevere malaria kills one million people every year, mostly children. Dilaforette is developing a heparin analogue, sevuparin, for the treatment of severe malaria that prevents infected cells’ ability to block blood vessels. |
Biosergen ASBiosergen develops new antibiotics for the treatment of fungal diseases. www.biosergen.com |
|
Source: 1) WHO, The Global Burden of Disease: 2004 Update, 2008